Blueshift Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Blueshift Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,207	Closed	-$277K	–	611
2025 Q2	$277K	Buy	16,207 +8,566	+112%	+$365K	0.09%	309
2025 Q1	$488K	Buy	+7,641	New	+$804K	0.19%	157
2024 Q4	–	Sell	-2,096	Closed	-$262K	–	504
2024 Q3	$262K	Buy	+2,096	New	+$290K	0.06%	297
2023 Q3	–	Sell	-5,912	Closed	-$677K	–	415
2023 Q2	$677K	Buy	+5,912	New	+$762K	0.26%	99
2022 Q2	–	Sell	-6,101	Closed	-$477K	–	984
2022 Q1	$477K	Buy	6,101 +3,180	+109%	+$244K	0.04%	462
2021 Q4	$263K	Buy	+2,921	New	+$250K	0.02%	673
2021 Q3	–	Sell	-6,730	Closed	-$523K	–	1284
2021 Q2	$523K	Buy	+6,730	New	+$510K	0.03%	550
2020 Q4	–	Sell	-3,025	Closed	-$425K	–	867
2020 Q3	$425K	Buy	+3,025	New	+$460K	0.06%	380
2019 Q4	–	Sell	-3,101	Closed	-$234K	–	1025
2019 Q3	$234K	Buy	+3,101	New	+$366K	0.04%	600

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Blueshift Asset Management's SRPT Position: Q3 2025 in Review

Blueshift Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 16,207 shares — an estimated $277K sold.

Blueshift Asset Management first reported a position in SRPT in Q3 2019 and held it in 9 quarters. The position peaked at $677K in Q2 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Blueshift Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Blueshift Asset Management sold 16,207 Sarepta Therapeutics shares in Q3 2025, an estimated $277K.
Blueshift Asset Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 9 quarters.
Blueshift Asset Management's Sarepta Therapeutics position peaked at $677K in Q2 2023.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Blueshift Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.